Dendritic function of tau mediates amyloid-β toxicity in alzheimer's disease mouse models

Cell

Volumn 142, Issue 3, 2010, Pages 387-397

  Ittner, Lars M ^a   Ke, Yazi D ^a   Delerue, Fabien ^a   Bi, Mian ^a   Gladbach, Amadeus ^a   van Eersel, Janet ^a   Wölfing, Heidrun ^a   Chieng, Billy C ^a   Christie, MacDonald J ^a   Napier, Ian A ^a   Eckert, Anne ^b   Staufenbiel, Matthias ^c   Hardeman, Edna ^d   Götz, Jürgen ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF BASEL   (Switzerland)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

HUMDISEASE; MOLNEURO

Indexed keywords

AMYLOID BETA PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; POSTSYNAPTIC DENSITY PROTEIN 95; PROTEIN KINASE FYN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; EXCITOTOXICITY; MOUSE; NONHUMAN; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

MUS; MUS MUSCULUS;

EID: 77955322042     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2010.06.036     Document Type: Article

References (54)

1. Aarts M., Liu Y., Liu L., Besshoh S., Arundine M., Gurd J.W., Wang Y.T., Salter M.W., Tymianski M. Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science 2002, 298:846-850.
2. Ashe K.H. A tale about tau. N. Engl. J. Med. 2007, 357:933-935.
3. Ballatore C., Lee V.M., Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 2007, 8:663-672.
4. Busche M.A., Eichhoff G., Adelsberger H., Abramowski D., Wiederhold K.H., Haass C., Staufenbiel M., Konnerth A., Garaschuk O. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science 2008, 321:1686-1689.
5. Butner K.A., Kirschner M.W. Tau protein binds to microtubules through a flexible array of distributed weak sites. J. Cell Biol. 1991, 115:717-730.
6. Calhoun M.E., Wiederhold K.H., Abramowski D., Phinney A.L., Probst A., Sturchler-Pierrat C., Staufenbiel M., Sommer B., Jucker M. Neuron loss in APP transgenic mice. Nature 1998, 395:755-756.
7. Chin J., Palop J.J., Yu G.Q., Kojima N., Masliah E., Mucke L. Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J. Neurosci. 2004, 24:4692-4697.
8. Chin J., Palop J.J., Puoliväli J., Massaro C., Bien-Ly N., Gerstein H., Scearce-Levie K., Masliah E., Mucke L. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 2005, 25:9694-9703.
9. Chishti M.A., Yang D.S., Janus C., Phinney A.L., Horne P., Pearson J., Strome R., Zuker N., Loukides J., French J., et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 2001, 276:21562-21570.
10. Crowther T., Goedert M., Wischik C.M. The repeat region of microtubule-associated protein tau forms part of the core of the paired helical filament of Alzheimer's disease. Ann. Med. 1989, 21:127-132.
11. Dixit R., Ross J.L., Goldman Y.E., Holzbaur E.L. Differential regulation of dynein and kinesin motor proteins by tau. Science 2008, 319:1086-1089.
12. Drechsel D.N., Hyman A.A., Cobb M.H., Kirschner M.W. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol. Biol. Cell 1992, 3:1141-1154.
13. El Khoury J., Toft M., Hickman S.E., Means T.K., Terada K., Geula C., Luster A.D. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 2007, 13:432-438.
14. Geschwind D.H. Tau phosphorylation, tangles, and neurodegeneration: the chicken or the egg?. Neuron 2003, 40:457-460.
15. Goedert M., Wischik C.M., Crowther R.A., Walker J.E., Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc. Natl. Acad. Sci. USA 1988, 85:4051-4055.
16. Götz J., Ittner L.M. Animal models of Alzheimer's disease and frontotemporal dementia. Nat. Rev. Neurosci. 2008, 9:532-544.
17. Götz J., Chen F., Barmettler R., Nitsch R.M. Tau filament formation in transgenic mice expressing P301L tau. J. Biol. Chem. 2001, 276:529-534.
18. Götz J., Chen F., van Dorpe J., Nitsch R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001, 293:1491-1495.
19. Grant S.G., O'Dell T.J., Karl K.A., Stein P.L., Soriano P., Kandel E.R. Impaired long-term potentiation, spatial learning, and hippocampal development in fyn mutant mice. Science 1992, 258:1903-1910.
20. Haass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B.L., Lieberburg I., Koo E.H., Schenk D., Teplow D.B., et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992, 359:322-325.
21. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
22. Kelly P.H., Bondolfi L., Hunziker D., Schlecht H.P., Carver K., Maguire E., Abramowski D., Wiederhold K.H., Sturchler-Pierrat C., Jucker M., et al. Progressive age-related impairment of cognitive behavior in APP23 transgenic mice. Neurobiol. Aging 2003, 24:365-378.
23. Kim E., Sheng M. PDZ domain proteins of synapses. Nat. Rev. Neurosci. 2004, 5:771-781.
24. Kojima N., Ishibashi H., Obata K., Kandel E.R. Higher seizure susceptibility and enhanced tyrosine phosphorylation of N-methyl-D-aspartate receptor subunit 2B in fyn transgenic mice. Learn. Mem. 1998, 5:429-445.
25. Kornau H.C., Schenker L.T., Kennedy M.B., Seeburg P.H. Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science 1995, 269:1737-1740.
26. Ksiezak-Reding H., Yen S.H. Structural stability of paired helical filaments requires microtubule-binding domains of tau: a model for self-association. Neuron 1991, 6:717-728.
27. Kuo Y.M., Beach T.G., Sue L.I., Scott S., Layne K.J., Kokjohn T.A., Kalback W.M., Luehrs D.C., Vishnivetskaya T.A., Abramowski D., et al. The evolution of A beta peptide burden in the APP23 transgenic mice: implications for A beta deposition in Alzheimer disease. Mol. Med. 2001, 7:609-618.
28. Lalonde R., Dumont M., Staufenbiel M., Strazielle C. Neurobehavioral characterization of APP23 transgenic mice with the SHIRPA primary screen. Behav. Brain Res. 2005, 157:91-98.
29. Lee G., Cowan N., Kirschner M. The primary structure and heterogeneity of tau protein from mouse brain. Science 1988, 239:285-288.
30. Lee G., Newman S.T., Gard D.L., Band H., Panchamoorthy G. Tau interacts with src-family non-receptor tyrosine kinases. J. Cell Sci. 1998, 111:3167-3177.
31. Leissring M.A., Farris W., Chang A.Y., Walsh D.M., Wu X., Sun X., Frosch M.P., Selkoe D.J. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003, 40:1087-1093.
32. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001, 293:1487-1491.
33. Maas T., Eidenmüller J., Brandt R. Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments. J. Biol. Chem. 2000, 275:15733-15740.
34. Minkeviciene R., Rheims S., Dobszay M.B., Zilberter M., Hartikainen J., Fülöp L., Penke B., Zilberter Y., Harkany T., Pitkänen A., Tanila H. Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J. Neurosci. 2009, 29:3453-3462.
35. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000, 20:4050-4058.
36. Nakazawa T., Komai S., Tezuka T., Hisatsune C., Umemori H., Semba K., Mishina M., Manabe T., Yamamoto T. Characterization of Fyn-mediated tyrosine phosphorylation sites on GluR epsilon 2 (NR2B) subunit of the N-methyl-D-aspartate receptor. J. Biol. Chem. 2001, 276:693-699.
37. Palop J.J., Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch. Neurol. 2009, 66:435-440.
38. Palop J.J., Chin J., Roberson E.D., Wang J., Thwin M.T., Bien-Ly N., Yoo J., Ho K.O., Yu G.Q., Kreitzer A., et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007, 55:697-711.
39. Phillips G.R., Huang J.K., Wang Y., Tanaka H., Shapiro L., Zhang W., Shan W.S., Arndt K., Frank M., Gordon R.E., et al. The presynaptic particle web: ultrastructure, composition, dissolution, and reconstitution. Neuron 2001, 32:63-77.
40. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.Q., Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
41. Roche K.W., Standley S., McCallum J., Dune Ly C., Ehlers M.D., Wenthold R.J. Molecular determinants of NMDA receptor internalization. Nat. Neurosci. 2001, 4:794-802.
42. Rong Y., Lu X., Bernard A., Khrestchatisky M., Baudry M. Tyrosine phosphorylation of ionotropic glutamate receptors by Fyn or Src differentially modulates their susceptibility to calpain and enhances their binding to spectrin and PSD-95. J. Neurochem. 2001, 79:382-390.
43. Röskam S., Neff F., Schwarting R., Bacher M., Dodel R. APP transgenic mice: the effect of active and passive immunotherapy in cognitive tasks. Neurosci. Biobehav. Rev. 2010, 34:487-499.
44. Salter M.W., Kalia L.V. Src kinases: a hub for NMDA receptor regulation. Nat. Rev. Neurosci. 2004, 5:317-328.
45. Selkoe D.J. Alzheimer's disease: genotypes, phenotypes, and treatments. Science 1997, 275:630-631.
46. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
47. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
48. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Bürki K., Frey P., Paganetti P.A., et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA 1997, 94:13287-13292.
49. Tezuka T., Umemori H., Akiyama T., Nakanishi S., Yamamoto T. PSD-95 promotes Fyn-mediated tyrosine phosphorylation of the N-methyl-D-aspartate receptor subunit NR2A. Proc. Natl. Acad. Sci. USA 1999, 96:435-440.
50. Tucker K.L., Meyer M., Barde Y.A. Neurotrophins are required for nerve growth during development. Nat. Neurosci. 2001, 4:29-37.
51. Van Dam D., D'Hooge R., Staufenbiel M., Van Ginneken C., Van Meir F., De Deyn P.P. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur. J. Neurosci. 2003, 17:388-396.
52. Weingarten M.D., Lockwood A.H., Hwo S.Y., Kirschner M.W. A protein factor essential for microtubule assembly. Proc. Natl. Acad. Sci. USA 1975, 72:1858-1862.
53. Yagi T., Aizawa S., Tokunaga T., Shigetani Y., Takeda N., Ikawa Y. A role for Fyn tyrosine kinase in the suckling behaviour of neonatal mice. Nature 1993, 366:742-745.
54. Zhao L., Ma Q.L., Calon F., Harris-White M.E., Yang F., Lim G.P., Morihara T., Ubeda O.J., Ambegaokar S., Hansen J.E., et al. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat. Neurosci. 2006, 9:234-242.